{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T12:01:18Z","timestamp":1792324878204,"version":"4.4.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"30","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,25]]},"abstract":"<jats:p>Advanced non-small cell lung cancer (NSCLC) represents a significant challenge in oncology, particularly when accompanied by distant metastases or when surgical resection is not feasible. These conditions are typically associated with poor prognosis and variable responses to treatment. Traditional chemotherapy, while commonly used, has limited efficacy and is often associated with substantial adverse effects, which can compromise survival outcomes. In recent years, targeted therapy and immunotherapy have emerged as promising alternatives for the treatment of advanced NSCLC. This retrospective cohort study aimed to evaluate the efficacy and safety of a combination regimen consisting of carboplatin, paclitaxel, bevacizumab, or gefitinib in patients with advanced NSCLC. A total of 312 patients, diagnosed and treated between January 2019 and December 2023, were included in the analysis. Patients were categorized into non-epidermal growth factor receptor gene mutation group (Group A\u2005+\u2005Group B) and epidermal growth factor receptor gene mutation group (Group C\u2005+\u2005Group D) according to gene mutation. The treatment regimens were divided into 4 groups: Group A (carboplatin\u2005+\u2005paclitaxel combined with bevacizumab treatment), Group B (carboplatin\u2005+\u2005paclitaxel treatment), Group C (carboplatin\u2005+\u2005paclitaxel combined with gefitinib treatment), and Group D (carboplatin\u2005+\u2005paclitaxel treatment). The results demonstrated that the experimental groups (A and C) exhibited significantly superior short-term efficacy compared to the control groups (B and D), with notable improvements in both the objective response rate and disease control rate (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05). Survival analysis further revealed that the median progression-free survival and overall survival were significantly longer in Groups A and C than in Groups B and D (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001). While the experimental groups experienced a higher incidence of adverse events, particularly hypertension, diarrhea, constipation, and rash, most of these were manageable. In conclusion, the combination of carboplatin, paclitaxel, bevacizumab, or gefitinib significantly improved progression-free survival and overall survival in patients with advanced NSCLC, offering superior efficacy over conventional regimens, with manageable side effects. These findings warrant further investigation to confirm the long-term benefits and optimize treatment strategies for advanced NSCLC.<\/jats:p>","DOI":"10.1097\/md.0000000000043300","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T09:00:42Z","timestamp":1753952442000},"page":"e43300","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of first-line treatment options for advanced non-small cell lung cancer: A retrospective study"],"prefix":"10.1097","volume":"104","author":[{"given":"Zhaosheng","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Longyan First Hospital Affiliated to Fujian Medical University, Longyan, Fujian Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglian","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hospital Infection Management, Longyan First Hospital Affiliated to Fujian Medical University, Longyan, Fujian Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenying","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Longyan First Hospital Affiliated to Fujian Medical University, Longyan, Fujian Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9126-722X","authenticated-orcid":false,"given":"Kaijun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Longyan First Hospital Affiliated to Fujian Medical University, Longyan, Fujian Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20251014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-24223-1_1","article-title":"Lung cancer statistics.","volume":"893","author":"Torre","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"R2-20251014","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"issue":"3 Suppl","key":"R3-20251014","doi-asserted-by":"crossref","first-page":"29S","DOI":"10.1378\/chest.07-1347","article-title":"Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).","volume":"132","author":"Alberg","year":"2007","journal-title":"Chest"},{"key":"R4-20251014","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.1016\/S1470-2045(21)00383-1","article-title":"Revisiting neoadjuvant therapy in non-small-cell lung cancer.","volume":"22","author":"Saw","year":"2021","journal-title":"Lancet Oncol"},{"key":"R5-20251014","doi-asserted-by":"crossref","first-page":"103194","DOI":"10.1016\/j.critrevonc.2020.103194","article-title":"Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives.","volume":"157","author":"Imyanitov","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"R6-20251014","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1097\/CM9.0000000000002750","article-title":"Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: a systematic review and network meta-analysis.","volume":"136","author":"Li","year":"2023","journal-title":"Chin Med J (Engl)"},{"key":"R7-20251014","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1200\/JCO.2012.47.9626","article-title":"PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.","volume":"31","author":"Patel","year":"2013","journal-title":"J Clin Oncol"},{"key":"R8-20251014","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1200\/JCO.1999.17.1.409","article-title":"Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin.","volume":"17","author":"Go","year":"1999","journal-title":"J Clin Oncol"},{"key":"R9-20251014","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/j.1875-9114.1994.tb02785.x","article-title":"Paclitaxel (taxol).","volume":"14","author":"Kohler","year":"1994","journal-title":"Pharmacotherapy"},{"key":"R10-20251014","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","article-title":"Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial.","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol"},{"key":"R11-20251014","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","article-title":"Lung cancer: current therapies and new targeted treatments.","volume":"389","author":"Hirsch","year":"2017","journal-title":"Lancet"},{"key":"R12-20251014","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000488340","article-title":"Tumor angiogenesis: a key target for cancer therapy.","volume":"41","author":"Marm\u00e9","year":"2018","journal-title":"Oncol Res Treat"},{"key":"R13-20251014","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1186\/s12885-021-08136-5","article-title":"Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials.","volume":"21","author":"Huang","year":"2021","journal-title":"BMC Cancer"},{"key":"R14-20251014","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1186\/s12885-022-09918-1","article-title":"Genome-wide DNA methylation signature predict clinical benefit of bevacizumab in non-small cell lung cancer.","volume":"22","author":"Li","year":"2022","journal-title":"BMC Cancer"},{"key":"R15-20251014","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"R16-20251014","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s43018-022-00351-8","article-title":"An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer.","volume":"3","author":"To","year":"2022","journal-title":"Nat Cancer"},{"key":"R17-20251014","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R18-20251014","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1586\/14737140.2016.1170596","article-title":"Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles.","volume":"16","author":"Rossi","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"key":"R19-20251014","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","article-title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"key":"R20-20251014","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","article-title":"Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer [published correction appears in Cancer Discov. 2022 Jun 2;12(6):1598. doi: 10.1158\/2159-8290.CD-22-0365.].","volume":"12","author":"J\u00e4nne","year":"2022","journal-title":"Cancer Discov"},{"key":"R21-20251014","doi-asserted-by":"crossref","first-page":"n2363","DOI":"10.1136\/bmj.n2363","article-title":"Advances in systemic therapy for non-small cell lung cancer.","volume":"375","author":"Miller","year":"2021","journal-title":"BMJ"},{"key":"R22-20251014","first-page":"240","volume":"51","author":"Shiraishi","year":"2024","journal-title":"Gan To Kagaku Ryoho"},{"key":"R23-20251014","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.annonc.2021.06.004","article-title":"Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer.","volume":"32","author":"Sugawara","year":"2021","journal-title":"Ann Oncol"},{"key":"R24-20251014","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer.","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"R25-20251014","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1179\/ACB.66.1.2062508","article-title":"Epidermal growth factor receptor targeted therapies for solid tumours.","volume":"66","author":"Van den Eynde","year":"2011","journal-title":"Acta Clin Belg"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T17:01:38Z","timestamp":1760461298000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":25,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000043300","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]}}}